Year Published
- 2008 (1) Apply 2008 filter
- 2009 (15) Apply 2009 filter
- 2010 (21) Apply 2010 filter
- 2011 (7) Apply 2011 filter
- 2012 (18) Apply 2012 filter
- 2013 (6) Apply 2013 filter
- 2014 (2) Apply 2014 filter
- 2015 (3) Apply 2015 filter
- 2016 (4) Apply 2016 filter
- (-) Remove 2017 filter 2017
- (-) Remove 2018 filter 2018
- 2019 (1) Apply 2019 filter
- 2020 (1) Apply 2020 filter
- 2021 (0)
Research Topics
Populations
Types of Research
- Data Analysis (3) Apply Data Analysis filter
- Literature Review (3) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (0)
Geography
- East Africa Region and Selected Countries (2) Apply East Africa Region and Selected Countries filter
- Global (4) Apply Global filter
- South Asia Region and Selected Countries (2) Apply South Asia Region and Selected Countries filter
- Southern Africa Region and Selected Countries (0)
- Sub-Saharan Africa (2) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (1) Apply West Africa Region and Selected Countries filter
Dataset
Current search
- (-) Remove 2017 filter 2017
- (-) Remove Development Finance & Policy filter Development Finance & Policy
- (-) Remove 2018 filter 2018
- (-) Remove Market & Value Chain Analysis filter Market & Value Chain Analysis
- (-) Remove Global & Regional Public Goods filter Global & Regional Public Goods
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
According to AGRA's 2017 Africa Agriculture Status Report, smallholder farmers make up to about 70% of the population in Africa. The report finds that 500 million smallholder farms around the world provide livelihoods for more than 2 billion people and produce about 80% of the food in sub-Saharan Africa and Asia. Many development interventions and policies therefore target smallholder farm households with the goals of increasing their productivity and promoting agricultural transformation. Of particular interest for agricultural transformation is the degree to which smallholder farm households are commercializating their agricultural outputs, and diversifying their income sources away from agriculture. In this project, EPAR uses data from the World Bank's Living Standards Measurement Study - Integrated Surveys on Agriculture (LSMS-ISA) to analyze and compare characteristics of smallholder farm households at different levels of crop commercialization and reliance on farm income, and to evaluate implications of using different criteria for defining "smallholder" households for conclusions on trends in agricultural transformation for those households.
An ongoing stream of EPAR research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. For this project, we seek to summarize the key public good characteristics of R&D investment for agriculture in general and for different subsets of crops, and hypothesize how these characteristics might be expected to affect public, private, or philanthropic funders’ investment decisions.
The concept of global public goods represents a framework for organizing and financing international cooperation in global health research and development (R&D). Advances in scientific and clinical knowledge produced by biomedical R&D can be considered public goods insofar as they can be used repeatedly (non-rival consumption) and it is difficult or costly to exclude non-payers from gaining access (non-excludable). This paper considers the public good characteristics of biomedical R&D in global health and describes the theoretical and observed factors in the allocation R&D funding by public, private, and philanthropic sources.